Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Elevance Health, Inc.
Bear Case (25th pct.)
-16.6% vs price
Base Case (Median)
-12.5% vs price
Bull Case (75th pct.)
26.8% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $219.38 | -43.2% | High (40%) |
| PE Comparable | $507.25 | 31.3% | Medium (25%) |
| Growth Trajectory DCF | $596.42 | 54.3% | Medium (20%) |
| Graham Number | $320.60 | -17.0% | Medium (40%) |
| EV/EBITDA | $338.13 | -12.5% | Medium (20%) |
| EV/FCF | $472.65 | 22.3% | Medium (20%) |
| Earnings Power Value | $323.96 | -16.2% | Medium (50%) |
Based on 7 out of 7 methods, ELV appears fairly valued at the current price of $386.43. The base case fair value of $338.13 implies 12.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.